PDS Biotechnology Future Growth
Future criteria checks 2/6
PDS Biotechnology is forecast to grow earnings and revenue by 6% and 73.1% per annum respectively while EPS is expected to grow by 17.8% per annum.
Key information
6.0%
Earnings growth rate
17.8%
EPS growth rate
Biotechs earnings growth | 24.6% |
Revenue growth rate | 73.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 11 Jun 2024 |
Recent future growth updates
Recent updates
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Jan 13PDS Biotech jumps 13% as FDA clears further development of lead asset
Oct 03PDS Biotechnology files for $150 mixed shelf offering
Aug 24PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
Aug 04PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
Jul 08PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
May 27PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
Feb 22PDS Biotech: Looking Attractive Despite 52-Week High Price
Sep 19PDS Biotech under pressure after pricing equity offering at $8.50
Jun 15PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101
Feb 03PDS Biotechnology gives new CFO ~202K stock grant
Jan 06PDS Biotech launches mid-stage PDS0101 combo trial in head & neck cancer
Nov 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 8 | -59 | -61 | -36 | 3 |
12/31/2025 | 0 | -60 | -55 | -36 | 4 |
12/31/2024 | N/A | -48 | -45 | -35 | 5 |
3/31/2024 | N/A | -44 | -30 | -30 | N/A |
12/31/2023 | N/A | -43 | -34 | -34 | N/A |
9/30/2023 | N/A | -51 | -33 | -33 | N/A |
6/30/2023 | N/A | -48 | -31 | -31 | N/A |
3/31/2023 | N/A | -42 | -33 | -33 | N/A |
12/31/2022 | N/A | -41 | -26 | -26 | N/A |
9/30/2022 | N/A | -28 | -23 | -23 | N/A |
6/30/2022 | N/A | -28 | -22 | -22 | N/A |
3/31/2022 | N/A | -22 | -15 | -15 | N/A |
12/31/2021 | N/A | -17 | -12 | -12 | N/A |
9/30/2021 | N/A | -15 | -13 | -13 | N/A |
6/30/2021 | N/A | -12 | -9 | -9 | N/A |
3/31/2021 | N/A | -14 | -14 | -14 | N/A |
12/31/2020 | N/A | -15 | -13 | -13 | N/A |
9/30/2020 | N/A | -15 | -14 | -14 | N/A |
6/30/2020 | N/A | -17 | -17 | -17 | N/A |
3/31/2020 | N/A | -18 | -18 | -18 | N/A |
12/31/2019 | N/A | -7 | -18 | -18 | N/A |
9/30/2019 | N/A | -5 | -13 | -13 | N/A |
6/30/2019 | N/A | 0 | -9 | -9 | N/A |
3/31/2019 | N/A | 4 | -5 | -5 | N/A |
12/31/2018 | N/A | -4 | -2 | -2 | N/A |
9/30/2018 | N/A | -2 | -2 | -2 | N/A |
12/31/2017 | N/A | -3 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PDSB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PDSB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PDSB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PDSB's revenue (73.1% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: PDSB's revenue (73.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PDSB's Return on Equity is forecast to be high in 3 years time